https://www.selleckchem.com/products/bi-4020.html
During the endoscopic follow-up, EV disappeared/improved in 36 (33.6%), were stable in 39 (36.4%) and worsened in 32 (29.9%) patients, all belonging to Group 2 (p=.001). Improvement in Baveno VI status was observed in 118/335 (35.2%, p.0001) of Group 2 patients and among those without pre-therapy EV, none developed EV throughout the follow-up. HCV-positive cirrhotic patients cured by DAAs showing baseline favourable Baveno VI status and no worsening during follow-up can safely avoid endoscopic screening and surveillance. Patients ha
Curtir
Comentario
Compartilhar
